FIRMAGON Drug Patent Profile

Which patents cover Firmagon, and when can generic versions of Firmagon launch?

Firmagon is a drug marketed by Ferring and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eight patent family members in twenty-four countries.

The generic ingredient in FIRMAGON is degarelix acetate. One supplier is listed for this compound. Additional details are available on the degarelix acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Firmagon

Firmagon was eligible for patent challenges on December 24, 2012.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 10, 2029. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (degarelix acetate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for FIRMAGON

International Patents:	108
US Patents:	9
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FIRMAGON

Paragraph IV (Patent) Challenges for FIRMAGON

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FIRMAGON	Powder for Injection	degarelix acetate	80 mg/vial and 120 mg/vial	022201	1	2019-12-20

US Patents and Regulatory Information for FIRMAGON

FIRMAGON is protected by nine US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-002	Dec 24, 2008		RX	Yes	Yes
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No

International Patents for FIRMAGON

When does loss-of-exclusivity occur for FIRMAGON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Jordan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FIRMAGON around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2009213748
Australia	2009213751
Brazil	PI0908127
Brazil	PI0908129

Supplementary Protection Certificates for FIRMAGON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1003774	91585	Luxembourg		PRODUCT NAME: DEGARELIX, EVENTUELLEMENT UN SEL PHARMACEUTIQUEMENT ACCEPTABE, TEL QUE L'ACETATE (FIRMAGON); REG. DATE: 20090217
1003774	SPC/GB09/028	United Kingdom		PRODUCT NAME: DEGARELIX OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT SUCH AS THE ACETATE; REGISTERED: UK EU/1/08/504/001 20090217; UK EU/1/08/504/002 20090217
1003774	300395	Netherlands		300395, 20180413, EXPIRES: 20230412
1003774	PA2009005,C1003774	Lithuania		PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217

Last updated: July 27, 2026

FIRMAGON (degarelix) investment scenario and fundamentals analysis: exclusivity, patent risk, regulatory status, and competitive outlook

Executive summary. FIRMAGON (degarelix, GnRH antagonist) is a mature oncology/hormone-therapy asset with an FDA-approved LHRH antagonist label for advanced hormone-sensitive prostate cancer (and related indications). Investment fundamentals are driven by (1) remaining legal exclusivity and Orange Book coverage tied to formulation and method claims, (2) competitive pressure versus LHRH agonists and LHRH antagonists (notably oral/long-acting options), and (3) clinical and payer preference dynamics after uptake of alternative degarelix and other GnRH-class therapies. At a practical level, the asset’s risk is concentrated in patent estate durability and the likelihood of generic or follow-on entry that can undercut pricing.

---

What patents protect FIRMAGON (degarelix) and how strong is the patent estate?

Featured snippet (answer): The patent estate for FIRMAGON is typically anchored in Orange Book-listed drug substance, composition/formulation, and method-of-use claims. Commercial strength depends on whether the remaining claims are still enforceable versus whether generic Paragraph IV or non-Paragraph IV pathways have clear design-around routes.

What types of patents usually control FIRMAGON exclusivity

For degarelix products, the enforceability landscape typically splits across:

• Drug substance / active ingredient claims (composition and salt form, synthesis and intermediates).
• Drug product and formulation patents (injectable composition, buffering, viscosity, solubilizers, lyophilization or reconstitution-related compositions, and stability).
• Method-of-use patents (patient selection, dosing regimens, switching strategies from other GnRH agents, or administration schedules).
• Manufacturing and process patents (sterility, particle size distribution, mixing/reconstitution parameters, and terminal processes).

How investors should score “estate strength” for mature injectables

Use a three-axis scoring model:

1. Remaining life: time to earliest expiration among Orange Book-listed patents and related non-Orange Book patents with likely injunction leverage.
2. Claim scope: whether independent claims cover the commercially used dosing regimen and formulation parameters.
3. Enforcement posture: whether prior litigations show sustained assertion and win rates in district court and the Federal Circuit.

Patent estate diligence checklist (what to verify in litigation-ready form)

• Orange Book “listed patents” for the exact NDC(s) for FIRMAGON injection (including both strengths and any package configurations).
• Status of each listed patent: expired, active, withdrawn, or stayed due to litigation or regulatory events.
• Known Paragraph IV filings tied to the relevant NDC(s) and whether they are certified against multiple patents or only certain listed claims.
• Whether challengers settled via licenses that preserve brand exclusivity or permit “at-risk” design-around.

---

When does FIRMAGON lose exclusivity and what expiration dates matter for generic entry?

Featured snippet (answer): For mature injectables, generic timing hinges on the earliest termination of Orange Book-listed patents that block the exact branded product NDC. Secondary delays can come from unresolved litigation, exclusivity triggers from new FDA approvals, or changes in the marketed composition that require different patent certifications.

Exclusivity timeline mechanics that drive market entry

• Patent expiration: The earliest date when at least one Orange Book-listed patent barrier falls away for the relevant NDC.
• Exclusivity periods: Even with patent expiry, 5-year/3-year exclusivity (new chemical entity or new clinical investigations) can delay approvals for certain categories. Mature products usually have no remaining statutory exclusivity but can have application-specific exclusivity depending on label/route updates.
• Litigation stays: If a generic submits a Paragraph IV certification and the brand sues within statutory windows, approvals can be stayed (typical framework: up to 30 months depending on case status).
• Settlement agreements: Authorized “launch entry dates” often shift the expected market timeline.

Investment relevance

Investors should map:

• Soft protection date (earliest likely entry due to partial claim invalidation or design-around).
• Hard protection date (earliest date with enforceable claims that still cover the commercial product and dosing regimen).

---

What generic entry risks exist for FIRMAGON (degarelix) and how likely is at-risk launch?

Featured snippet (answer): At-risk launch risk rises when remaining Orange Book patents are (a) narrow in scope, (b) weakened by litigation outcomes, or (c) already expired for key NDCs, leaving only claims that can be designed around.

How to quantify generic threat for an injectable

Injectable entrants face additional practical barriers beyond patents:

• Formulation reproducibility and stability targets during shelf-life.
• Reconstitution performance and delivery device compatibility.
• CGMP and validation for particle size distribution if applicable.
• Bioequivalence and bridging strategies based on pharmacokinetics.

Competitive strategy for would-be challengers

Common challenger pathways include:

• Filing for the same strength(s) and dose schedule, maximizing NDC coverage.
• Using a formulation or manufacturing process design-around if formulation patents remain strong.
• Targeting fewer strengths first if barriers differ by NDC.

What would drive “high probability” generic entry

• Multiple listed formulation/method patents approaching expiry.
• Litigation unfavorable to the brand on core claims.
• Successful challenger technical bridge that demonstrates pharmaceutical equivalence without triggering additional IP.

---

What is the Orange Book status of FIRMAGON and what NDCs are listed?

Featured snippet (answer): Orange Book listing is the controlling map for which patents must be challenged for a generic approval under the Hatch-Waxman framework. For FIRMAGON, the key diligence step is tying each listed patent to the exact NDC(s) and ensuring the certifications correspond to the branded dosage form (injectable) and strength.

How to structure the Orange Book dataset for investment decisions

Build a table by NDC:

• NDC
• Strength and presentation (dose units, kit configuration)
• Active ingredient: degarelix
• Patent numbers (drug substance, formulation, method-of-use, manufacturing)
• Expiration date per patent
• Current regulatory status of patent (listed, withdrawn, expired, superseded)
• Certification types for any known ANDA submissions (if publicly disclosed)
• Litigation status and “triggering” events (suit filed, stay imposed, settlement)

(A complete Orange Book-NDC-by-patent table requires the specific Orange Book dataset for FIRMAGON at the time of review, including current listed patents and statuses.)

---

How does FIRMAGON compare with competing GnRH antagonists and agonists (market and patent impact)?

Featured snippet (answer): Competition for degarelix is primarily class-based: other GnRH therapies for advanced prostate cancer. Differentiation comes from onset of testosterone suppression, dosing schedule convenience, switching behavior, tolerability, and payer access.

Key competitive comparisons investors track

• Patient convenience: dosing frequency and injection burden.
• Clinical protocol fit: bridging and transition from other androgen deprivation therapies.
• Tolerability profile: injection site reactions and discontinuation rates.
• Payer preference: formulary placement, step edits, and specialty pharmacy contracting.

Patent impact lens

Competitor product patent estates can affect market share even before generic entry:

• If a competitor has stronger exclusivity, it can command premium pricing or secure payer access.
• If competitors are entering generic markets, pricing pressure rises and reduces brand ROI.

---

What formulations are protected by FIRMAGON patents and what delivery system risks exist?

Featured snippet (answer): For injectable products, formulation patents often concentrate on composition and stability attributes that are hard to replicate without infringing. Delivery system and reconstitution instructions can also sit inside method or formulation claim scope.

Formulation patent clusters relevant to injectable GnRH antagonists

• Buffering and pH targeting for degarelix stability in aqueous injectable reconstitution systems.
• Solubilizer and excipient ranges.
• Lyophilized versus liquid presentation claims (where applicable).
• Particle size distribution control and reconstitution mixing parameters.
• Stability and shelf-life validation methods.

Why formulation matters for generic economics

Even if generic could overcome method patents, formulation IP can:

• Increase development time,
• Trigger design-around costs,
• Delay approval if bioequivalence is challenged,
• Increase litigation probability.

---

What method-of-use claims cover FIRMAGON dosing regimens and switching strategies?

Featured snippet (answer): Method-of-use patents typically cover patient selection and dosing regimens. These can block generic entry even when drug product patents are weakened, depending on how the dosing is claimed and whether a generic product label can omit or change the method claim trigger.

Method-of-use pathways for design-around

A generic might attempt:

• Label carve-outs that avoid infringing dosing regimens,
• Alternative dosing schedules,
• Product labeling differences that reduce direct induced infringement exposure.

Investment takeaway

Method patents can be “silent killers” for generics because they can keep the brand protected even when formulation barriers are partially overcome. Litigation history matters more than patent count alone.

---

What patent litigation affects FIRMAGON and which parties are challenging it?

Featured snippet (answer): Patent litigation risk is driven by whether ANDA challengers file Paragraph IV certifications and whether the brand asserts formulation and method-of-use claims strongly enough to block approval.

Litigation due diligence categories

• District court case(s) involving relevant NDC(s) and listed patents.
• Federal Circuit appeals (if any) that determine claim construction and enforceability.
• Settlement agreements that fix an entry date or licensing scope.
• Consent judgments or dismissals that clarify which claims were effectively abandoned.

What investors should treat as “material”

• Injunction or partial stay orders tied to specific patents.
• Claim construction wins for the brand that narrow or expand infringing scope.
• Settlement terms that specify:
  • launch timing,
  • whether multiple strengths are included,
  • whether the challenger remains free to market outside the licensed scope.

(A complete litigation map requires identifying the specific court dockets, case numbers, and asserted patents tied to FIRMAGON.)

---

What settlement agreements and licensing deals shape FIRMAGON market entry?

Featured snippet (answer): Settlements can shift the real-world generic entry date even when patents are not fully litigated to final judgment, often by specifying a “carve-out” entry schedule or cross-license scope.

What to extract from any known settlements

• Effective date and authorized entry date(s).
• Which strengths and presentations are covered.
• Patent scope included in the license (drug substance vs formulation vs method).
• Whether there is a shared pathway allowing later FDA supplements.

Why this matters for ROI

A settlement can produce a predictable earnings runway but can also create a “dormant threat” where later supplements bring new entry opportunities.

---

What is the FDA regulatory status of FIRMAGON and what label changes affect risk?

Featured snippet (answer): Regulatory status affects both competition and exclusivity. Label updates that trigger new clinical investigations can extend exclusivity, while post-market changes can introduce new patentable formulations or new Orange Book listings.

Investment-relevant regulatory checkpoints

• Current FDA-approved indications and any updates to dosing instructions.
• Safety-related labeling changes that affect switching behavior.
• Manufacturing changes (site, process, formulation) that can introduce new patents and new barriers.

---

How do biosimilar risks apply to FIRMAGON (degarelix)?

Featured snippet (answer): Biosimilar risk is low because degarelix is a small-molecule peptide-like drug (not a biologic) in the classic biosimilar sense. The competitive risk is primarily generic and follow-on injectable equivalents, not biosimilars.

What still can be “follow-on” risk

• Authorized generics or branded follow-ons.
• Pharmaceutical equivalents for the same NDC strengths.
• Overlapping therapeutic competitors in prostate cancer.

---

Commercial fundamentals: what drives FIRMAGON revenue exposure and pricing power?

Featured snippet (answer): FIRMAGON fundamentals are driven by durable demand in advanced prostate cancer treatment protocols, offset by payer-driven price pressure and class competition. Revenue tends to be resilient if clinical protocol preferences and formularies favor GnRH antagonists over substitutes.

Key commercial drivers

• Treatment initiation volume (new starts) and switching rates.
• Persistence and duration on therapy tied to regimen selection.
• Pricing and contracting structure with oncology and urology networks.
• Market share shifts from:
  • oral or alternative dosing GnRH therapies,
  • long-acting depot options,
  • generic competition in the therapeutic class.

What matters for an investment case

• Whether market share is stable or eroding.
• Whether price per unit holds as competitors offer lower net prices.
• Whether the asset faces a foreseeable generic entry event.

---

Investment scenario planning: three plausible outcomes for FIRMAGON over the next 3–7 years

Featured snippet (answer): Outcomes cluster into (A) continued brand durability, (B) partial erosion from generic/follow-on equivalents, and (C) accelerated share loss from class competition and pricing.

Scenario A: Brand durability with limited entry

• Core Orange Book barriers remain enforceable.
• Any challenger is delayed by litigation or design-around complexity.
• Payer positioning keeps FIRMAGON as a preferred injectable GnRH antagonist.

Scenario B: Entry with slower adoption

• Some patents expire while others constrain full-equivalence (label or formulation).
• Generic enters at a discount but faces switching friction and clinician inertia.
• Brand maintains share via contracting and patient-specific protocols.

Scenario C: Accelerated erosion

• Multiple core patents fall quickly or adverse claim construction narrows enforcement.
• ANDA approval permits broader market presence.
• Net price declines outpace volume gains, compressing contribution margin.

(A deterministic scenario requires actual Orange Book listing, patent expiration mapping, and any active litigation or settlement dates.)

---

Key Takeaways

• Value is patent- and NDC-specific. Investment durability depends on which Orange Book-listed patents remain enforceable for the exact marketed FIRMAGON strengths and presentations.
• Risk is concentrated in formulation and method-of-use coverage. Injectable equivalents often face higher design-around and development friction, but method and formulation claims can still block approvals.
• Commercial fundamentals track class competition and payer dynamics. Even without generic entry, net pricing and formulary placement determine ROI.
• Litigation and settlements can shift timelines materially. Market entry dates often depend more on case posture and settlement terms than on raw patent expiration arithmetic.

---

FAQs

1. How do Orange Book NDC changes affect generic certification strategy for FIRMAGON?
2. What patents typically remain after drug substance claims expire for injectable degarelix products?
3. Can a generic avoid FIRMAGON method-of-use infringement by changing the label dosing regimen?
4. What settlement terms most influence when generic injectable competitors can launch?
5. How does clinician preference between GnRH antagonists versus agonists change the revenue outlook for FIRMAGON?

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. Hatch-Waxman Act, 21 U.S.C. § 355 and related provisions. (n.d.). U.S. Code. https://uscode.house.gov/
3. FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm